创胜集团医药-B(06628)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06628 创胜集团医药-B

交易中 09-28 10:48:09

1.005

-0.040

-3.83%

最高1.010	最低0.970	成交量18.85万
今开0.970	昨收1.045	日振幅3.83%
总市值4.55亿	流通市值4.55亿	总股本4.53亿
成交额18.73万	换手率0.04%	流通股本4.53亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06628","market":"HK","secType":"STK","nameCN":"创胜集团医药-B","latestPrice":1.005,"timestamp":1790563106337,"preClose":1.045,"halted":0,"volume":188500,"delay":0,"changeRate":-0.03827751196172252,"floatShares":453000000,"shares":453000000,"eps":-0.49,"marketStatus":"交易中","change":-0.04,"latestTime":"09-28 10:48:09","open":0.97,"high":1.01,"low":0.97,"amount":187320,"amplitude":0.038278,"askPrice":1.005,"askSize":24000,"bidPrice":0.97,"bidSize":89000,"shortable":0,"etf":0,"ttmEps":-0.41,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1790568000000},"marketStatusCode":2,"adr":0,"listingDate":1632844800000,"exchange":"SEHK","adjPreClose":1.045,"openAndCloseTimeList":[[1790559000000,1790568000000],[1790571600000,1790582400000]],"volumeRatio":0.420037,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06628","defaultTab":"news","newsList":[{"id":"1110410521","title":"创胜集团医药-B：China Structural Reform Fund Corporation Limited减持，好仓比例降至5.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110410521","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110410521?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:32","pubTimestamp":1789983124,"startTime":"0","endTime":"0","summary":"China Structural Reform Fund Corporation Limited于2026年9月18日在联交所场内以每股均价0.88港元卖出创胜集团医药-B股份134.20万股，涉资约118.10万港元。属场内主动交易，即在二级市场直接买卖股份。China Structural Reform Fund Corporation Limited此次减持前持有创胜集团医药-B好仓2846.70万股，占比6.25%；减持后持股量为2712.50万股，好仓比例降至5.96%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669134354","title":"创胜集团医药-B盘中大涨超29% 获董事会主席钱雪明增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2669134354","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669134354?lang=zh_cn&edition=full","pubTime":"2026-09-21 11:38","pubTimestamp":1789961880,"startTime":"0","endTime":"0","summary":"模拟交易客户端创胜集团医药-B盘中大涨超29%，截至发稿，股价上涨21.54%，现报1.185港元，成交额520.75万港元。据香港联交所最新数据显示，9月17日，钱雪明增持创胜集团医药-B10万股，每股作价0.8552港元，总金额为8.552万港元。此前，创胜集团医药-B披露2026年中期业绩，该集团取得收入2359.7万元，同比增长770.42%；公司拥有人应占亏损6734.7万元，同比收窄38.66%；每股亏损0.27元。公告称，收入增加主要由于对外许可收入及CDMO服务增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-21/doc-inisqeue5918473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","159938","06628","BK1574","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669168131","title":"港股异动 | 创胜集团医药-B(06628.HK)涨超24% 获董事会主席钱雪明增持公司股份 上半年对外许可收入增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2669168131","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669168131?lang=zh_cn&edition=full","pubTime":"2026-09-21 11:04","pubTimestamp":1789959878,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","BK1515","06628","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139535","title":"创胜集团医药-B盘中涨超16%，十部门联合印发《医药工业发展“十五五”规划》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139535","media":"同花顺","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139535?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:06","pubTimestamp":1789956360,"startTime":"0","endTime":"0","summary":"9月21日，创胜集团医药-B(06628.HK)盘中涨超16%，截至9时56分，涨16.41%，报1.14港元/股，成交额122.85万港元。消息面上，9月18日，工信部等十部门联合印发《医药工业发展“十五五”规划》 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260921/c680110508.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260921/c680110508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1574","09939","BK1515","159938","06628","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668902759","title":"创胜集团医药-B获钱雪明增持10万股 每股作价0.8552港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668902759","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668902759?lang=zh_cn&edition=full","pubTime":"2026-09-20 10:09","pubTimestamp":1789870140,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端香港联交所最新数据显示，9月17日，钱雪明增持创胜集团医药-B（06628）10万股，每股作价0.8552港元，总金额为8.552万港元。增持后最新持股数目为3860.00万股，最新持股比例为8.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-20/doc-inismvpc2527538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159938","09939","EWH","BK1161","BK1515","06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668928626","title":"钱雪明增持创胜集团医药-B(06628)10万股 每股作价0.8552港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668928626","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668928626?lang=zh_cn&edition=full","pubTime":"2026-09-18 19:15","pubTimestamp":1789730116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月17日，钱雪明增持创胜集团医药-B10万股，每股作价0.8552港元，总金额为8.552万港元。增持后最新持股数目为3860.00万股，最新持股比例为8.47%。补充资料：Box 28: represents  400,000 Shares represents options granted under the Share Incentive Scheme on 19 December 2022;  4,277,188 Shares to be issued upon vesting of share awards granted under the Share Incentive Scheme on 26 January 2023; and  3,641,024 Shares to be subscribed upon full exercise of options.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","EWH","09939","159938","BK1574","06628","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182293206","title":"创胜集团医药-B：钱雪明增持，好仓比例升至8.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182293206","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182293206?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:25","pubTimestamp":1789723543,"startTime":"0","endTime":"0","summary":"钱雪明于2026年9月17日在联交所场内以每股均价0.8552港元买入创胜集团医药-B股份10万股，涉资约8.55万港元，属场内主动交易，即在二级市场直接买卖股份。钱雪明此次增持前持有创胜集团医药-B好仓3850.00万股，占比8.45%；增持后持股量为3860.00万股，好仓比例升至8.47%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106512251","title":"创胜集团医药-B：钱雪明增持，好仓比例升至8.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106512251","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106512251?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:53","pubTimestamp":1789120380,"startTime":"0","endTime":"0","summary":"钱雪明于2026年9月9日以每股均价0.9950港元买入创胜集团医药-B股份4.00万股，涉资约3.98万港元。钱雪明此次增持前持有创胜集团医药-B好仓3837.00万股，占比8.42%；增持后持股量为3841.00万股，好仓比例升至8.43%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122263180","title":"创胜集团医药-B：钱雪明增持，好仓比例升至8.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1122263180","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122263180?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:20","pubTimestamp":1789118446,"startTime":"0","endTime":"0","summary":"钱雪明于2026年9月8日以每股均价1.0221港元买入创胜集团医药-B股份31.00万股，涉资约31.69万港元。钱雪明此次增持前持有创胜集团医药-B好仓3806.00万股，占比8.35%；增持后持股量为3837.00万股，好仓比例升至8.42%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102494551","title":"创胜集团医药-B：钱雪明增持，好仓比例升至8.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102494551","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102494551?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:13","pubTimestamp":1789118013,"startTime":"0","endTime":"0","summary":"钱雪明于2026年9月10日以每股均价0.925港元买入创胜集团医药-B股份2.00万股，涉资约1.85万港元。钱雪明此次增持前持有创胜集团医药-B好仓3841.00万股，占比8.43%；增持后持股量为3843.00万股，好仓比例升至8.44%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199398567","title":"创胜集团医药-B（06628）资产购买相关普通决议获股东特别大会全票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1199398567","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199398567?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:56","pubTimestamp":1788962172,"startTime":"0","endTime":"0","summary":"创胜集团医药-B9月9日公告披露，公司于2026年9月9日在中国苏州召开的股东特别大会就资产购买协议及相关授权事项进行表决，普通决议案以100.00%的赞成票获得通过。具体投票结果为：赞成票2.18亿股，反对票0股，投票总数同为217,532,987股。公告显示，截至股东特别大会当日，公司已发行股份总数为455,578,999股，其中2,516,500股为库藏股份，不具备表决权。扣除库藏股份后，可出席并有权对决议案投票的股份总数为433,378,061股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118201250","title":"创胜集团医药-B授予药明生物Hicb平台及Excelpro细胞培养基非独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1118201250","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118201250?lang=zh_cn&edition=full","pubTime":"2026-09-09 20:02","pubTimestamp":1788955330,"startTime":"0","endTime":"0","summary":"创胜集团医药-B（TRANSCENTA-B）宣布，已向药明生物（WUXI BIO）授予其Hicb平台及Excelpro细胞培养基的非独家许可。\n这一举措标志着两家生物医药企业之间的深度合作。通过该协议，药明生物将获得使用创胜集团先进的Hicb抗体发现平台和高效的Excelpro细胞培养基技术的权限。\n值得注意的是，非独家授权的形式允许创胜集团未来继续向其他合作伙伴提供相同技术，而药明生物则能借此增强其研发和生产能力。业界观察人士认为，此类技术共享有助于加速生物制剂的开发进程，并可能对行业竞争格局产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B0JY6N72.USD","LU0348735423.USD","LU3063872942.SGD","LU1880383366.USD","LU0327786744.USD","SG9999002463.SGD","LU0181495838.USD","LU0456827905.SGD","LU0856984785.SGD","LU0039217434.USD","LU0588546209.SGD","LU0326950275.SGD","LU1794554557.SGD","LU0516422952.EUR","LU0359202008.SGD","BK1161","LU0516422366.SGD","LU0708995583.HKD","LU0819121731.USD","LU0979878070.USD","KURE","LU0043850808.USD","LU0572944931.SGD","LU0128526141.USD","LU1720050803.USD","LU1688375341.USD","LU0359201612.USD","LU0029874061.USD","BK1610","06628","LU2039709279.SGD","02269","LU0140636845.USD","BK1576","LU0417516902.SGD","LU0516423091.SGD","LU0320764599.SGD","SG9999002562.SGD","LU0823426480.USD","LU1242518931.SGD","LU0348825331.USD","LU1242518857.USD","LU0516422440.USD","LU0052750758.USD","BK1589","BK1141","BK1521","LU0516423174.USD","LU0823426308.USD","LU0051755006.USD","LU0307460666.USD","LU0417516738.SGD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150566258","title":"创胜集团与药明生物达成战略合作，加速Hicb连续生物工艺技术商业化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=1150566258","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150566258?lang=zh_cn&edition=full","pubTime":"2026-09-09 20:01","pubTimestamp":1788955311,"startTime":"0","endTime":"0","summary":"创胜集团医药-B（TRANSCENTA-B）与药明生物宣布达成一项战略合作协议，旨在共同推进Hicb连续生物工艺技术的商业化落地。\n此次合作聚焦于将这一创新性技术加速推向市场。双方将整合各自优势资源，协同发力，以期在生物制药领域抢占先机。Hicb技术被视为生物工艺领域的重要突破，其商业化进程的提速有望为行业带来新的变革。\n通过强强联合，两家企业意在缩短技术从研发到应用的时间窗口，为全球患者提供更高效、更经济的生物药解决方案。该战略伙伴关系的建立，也标志着双方在推动先进制造技术产业化方面迈出了坚实一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104849260","title":"创胜集团医药-B更新2026年8月股份变动月报表，股本保持基本稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1104849260","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104849260?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:46","pubTimestamp":1788511603,"startTime":"0","endTime":"0","summary":"创胜集团医药有限公司于2026年9月4日发布截至2026年8月31日止月份的证券变动月报表，披露了公司本月内的股本及股份变动情况。截至2026年8月31日，创胜集团医药-B的公众持股量符合香港联交所股份上市规则相关要求。公司亦在公告中声明，本月所有证券发行和库存股份转让已获公司董事会正式授权，并严格遵守香港联交所《上市规则》及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663309068","title":"创胜集团医药-B(06628.HK)：程根宏获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2663309068","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663309068?lang=zh_cn&edition=full","pubTime":"2026-08-29 01:04","pubTimestamp":1787936651,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06628","BK1515","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176261525","title":"创胜集团医药-B（06628）公布最新董事会及下设委员会成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1176261525","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176261525?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:59","pubTimestamp":1787929144,"startTime":"0","endTime":"0","summary":"2026年8月28日，创胜集团医药-B在公告中披露公司董事会及其下设委员会最新成员组成，具体如下：。公告显示，公司董事会及各专门委员会的最新组成自公告日期起生效。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128401392","title":"创胜集团医药-B（06628）宣布2026年8月委任新独董并发放3万股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1128401392","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128401392?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:55","pubTimestamp":1787928940,"startTime":"0","endTime":"0","summary":"创胜集团医药-B8月28日公告，公司董事会决定自2026年8月28日起委任程根宏教授为独立非执行董事，任期三年。其亦于2019年至2025年期间出任亿帆医药股份有限公司独立董事，自2025年起担任上海爱科百发生物医药技术股份有限公司独立非执行董事。\\n\\n根据股份激励计划，30,000股奖励股份的授出已获全体独立非执行董事批准。程根宏教授已放弃就相关决议的投票权，且不计入董事会法定人数。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662091448","title":"创胜集团医药-B(06628)发布中期业绩 股东应占亏损6734.7万元 同比收窄38.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662091448","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662091448?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:47","pubTimestamp":1787928438,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B(06628)发布截至2026年6月30日止六个月中期业绩，该集团取得收入2359.7万元，同比增长770.42%;公司拥有人应占亏损6734.7万元，同比收窄38.66%;每股亏损0.27元。每股亏损0.16元。公告称，收入增加主要由于对外许可收入及CDMO服务增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK1574","159938","06628","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102126030","title":"创胜集团医药-B2026年中期营收2,360万元同比增774%，经调整净亏损6,500万元收窄34.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102126030","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102126030?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:17","pubTimestamp":1787923020,"startTime":"0","endTime":"0","summary":"创胜集团医药-B公告显示，截至2026年6月30日止六个月，实现收入2,360万元，同比增加774%。收入增长主要来自对外许可收入的新增贡献，以及合同开发与制造等业务的稳步推进。财报同期经调整净亏损6,500万元，相较于去年同期的9,940万元收窄34.6%。经调整净亏损减少，主要是因为管线推进相关的研发投入有所降低。创胜集团医药-B方面表示，公司将继续关注创新药临床试验推进，并加速与全球及区域制药企业展开战略合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"创胜集团医药-B2026年中期营收2,360万元同比增774%，经调整净亏损6,500万元收窄34.6%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122901322","title":"创胜集团医药-B拟于2026年9月9日召开股东特别大会 审议资产购买协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1122901322","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122901322?lang=zh_cn&edition=full","pubTime":"2026-08-25 06:10","pubTimestamp":1787609459,"startTime":"0","endTime":"0","summary":"创胜集团医药-B8月25日公告，公司将于2026年9月9日上午十时在中国苏州星湖街218号生物纳米园B6-501室举行股东特别大会。会议将以普通决议案形式审议并酌情批准以下事项：。根据香港联交所证券上市规则，股东特别大会上所有决议案将以投票方式表决。公司将于2026年9月4日至2026年9月9日暂停办理股份过户登记，以确定有资格出席并投票的股东名单。股东可通过电子会议系统线上观看股东特别大会，但线上参与不计入法定人数且无法线上投票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transcenta.com","stockEarnings":[{"period":"1week","weight":0.0718},{"period":"1month","weight":-0.0324},{"period":"3month","weight":-0.0586},{"period":"6month","weight":-0.5902},{"period":"1year","weight":-0.7728},{"period":"ytd","weight":-0.5071}],"compareEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0446},{"period":"3month","weight":0.0811},{"period":"6month","weight":-0.0177},{"period":"1year","weight":-0.0746},{"period":"ytd","weight":-0.0437}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"创胜集团医药有限公司是一家从事临床阶段生物制药的发现、研究、开发、制造和业务拓展的投资控股公司。该公司的产品包括MSB2311，TST001，TST005，TST002，TST004，TST003，TST008，MSB0254和TST006。该公司还提供合同开发和生产（CDMO）服务，主要包括工艺开发服务、GMP/cGMP生产服务、细胞株开发服务、样品检测服务、配方优化服务及成药性研究。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.077034},{"month":2,"riseRate":0.2,"avgChangeRate":0.209822},{"month":3,"riseRate":0.6,"avgChangeRate":0.021801},{"month":4,"riseRate":0.4,"avgChangeRate":0.025385},{"month":5,"riseRate":0.4,"avgChangeRate":0.017086},{"month":6,"riseRate":0,"avgChangeRate":-0.133694},{"month":7,"riseRate":0.2,"avgChangeRate":0.238284},{"month":8,"riseRate":0.2,"avgChangeRate":-0.078265},{"month":9,"riseRate":0.6,"avgChangeRate":0.063195},{"month":10,"riseRate":0.2,"avgChangeRate":-0.134792},{"month":11,"riseRate":0,"avgChangeRate":-0.134628},{"month":12,"riseRate":0.2,"avgChangeRate":-0.086836}],"exchange":"SEHK","name":"创胜集团医药-B","nameEN":"TRANSCENTA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创胜集团医药-B(06628)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创胜集团医药-B(06628)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创胜集团医药-B,06628,创胜集团医药-B股票,创胜集团医药-B股票老虎,创胜集团医药-B股票老虎国际,创胜集团医药-B行情,创胜集团医药-B股票行情,创胜集团医药-B股价,创胜集团医药-B股市,创胜集团医药-B股票价格,创胜集团医药-B股票交易,创胜集团医药-B股票购买,创胜集团医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创胜集团医药-B(06628)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创胜集团医药-B(06628)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}